(1) Notwithstanding section 24-1-136 (11)(a)(I), on or before December 1, 2021, and on or before December 1 each year thereafter, the state department shall submit a report to the governor, the president of the senate, and the speaker of the house of representatives concerning the operation of the program during the previous fiscal year. The report must include, at a minimum:
A list of the prescription drugs that were imported under the program;
The number of participating Canadian suppliers and eligible importers;
The number of prescriptions dispensed through the program;
The estimated cost savings during the previous fiscal year and to date;
A description of the methodology used to determine which prescription drugs shouldbe included on the wholesale prescription drug importation list established pursuant to section 25.5-2.5-203 (2)(a); and
Documentation demonstrating how the program ensures that:
The vendor verifies that Canadian suppliers participating in the program are in fullcompliance with relevant Canadian federal and provincial laws and regulations;
Prescription drugs imported under the program are not shipped, sold, or dispensedoutside of the state once in the possession of the eligible importer;
Prescription drugs imported under the program are pure, unadulterated, potent, andsafe;
The program does not put consumers at a higher health and safety risk than if theprogram did not exist; and
The program provides cost savings to the state on imported prescription drugs.
Source: L. 2019: Entire part added, (SB 19-005), ch. 184, p. 2072, § 3, effective August 2.